ADVERTISEMENT
LIVE DESK·Global markets desk·Last updated 14s ago
ADVERTISEMENT
Markets/EquitiesArticle

Texas Rep. Pete Sessions Sells Shares in AbbVie, Alphabet

The congressman’s office disclosed sales of stock in AbbVie and Alphabet on Sept. 18, each transaction valued between $15,001 and $50,000.

PA
Priya Anand · Equities & Earnings Desk · 21 Sept 2026 · 20:17 · 1 min read
Share
Texas Rep. Pete Sessions Sells Shares in AbbVie, Alphabet

U.S. Representative Pete Sessions, who represents Texas’s 17th Congressional District, sold shares in pharmaceutical maker AbbVie Inc. and Alphabet Inc., according to periodic transaction reports filed under the STOCK Act.

Both sales were executed on September 14, 2026, and the filings were submitted four days later on September 18. Each transaction fell within a reported dollar range of $15,001 to $50,000. The reports did not disclose whether either sale generated capital gains exceeding $200.

AbbVie shares were held in an Exchange Traded Individual Retirement Account, while the Alphabet position was held in an ET Investment account. Both filings carried the transaction type code “S,” indicating a sale, and were marked as new reports.

At the time of the transaction, AbbVie stock was trading at $265.34, hovering just below its 52-week high of $267.47. The drugmaker’s market capitalization stands at approximately $469 billion. Over the prior six months, AbbVie shares had climbed 31%. AbbVie has also increased its dividend for 14 consecutive years.

Sessions certified the accuracy of the disclosures, confirming compliance with the Stop Trading on Congressional Knowledge Act, which requires members of Congress to report brokerage transactions within 45 days of execution.

This article was produced with AI assistance and edited by a Finance Review Daily journalist.
ADVERTISEMENT
Share this story
PA
Written by
Priya Anand
Equities & Earnings Desk

Priya covers listed equities and corporate earnings, reading quarterly results and guidance for what they signal about sector health and forward valuations.

More from Priya Anand →
ADVERTISEMENT
Novara — A Smarter Way to Access Global Markets
ADVERTISEMENT